Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Antibody Expressing Mesothelin CAR-T in Advanced Malignancies
NCT03030001Phase 2Unknown
- Sponsor
- Ningbo Cancer Hospital
- Start
- Feb 2017
- Primary completion
- Dec 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of PD-1 antibody expressing mesothelin specific CAR-T cells in solid tumor, sponsored by Ningbo Cancer Hospital. Status: unknown.
02
Drugs
PD-1 antibody expressing mesothelin specific CAR-T cells
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03030001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030001.